Early infections in adult patients undergoing unrelated donor cord blood transplantation.
Early transplant-related mortality after cord blood transplantation from unrelated donors (UD-CBT) is close to 50%, mainly due to infectious complications. We have studied the incidence and characteristics of early infections (before day 100) in a series of 27 adult patients (median age 30 years, range 16-46) undergoing UD-CBT at a single institution. All 27 patients experienced at least one infectious episode and 18 (66%) suffered a severe infection. Bacteremia occurred in 55% of patients (13 with Gram-positive and 11 with Gram-negative microorganisms). Eleven of 19 CMV-seropositive patients (58%) developed CMV antigenemia and one patient had CMV disease. Fungal infections were documented in three patients (11%), comprising invasive fungal infections in two cases and a localized esophagitis in one. Ten patients (37%) died before day 100 after transplantation. Infection was considered the primary cause of death in four patients (sepsis by Acinetobacter spp. bacteremia in three cases) and contributed to death in another four. The most striking findings in this series were the high incidence of, and mortality due to multiresistant Acinetobacter spp. and the low incidence of and lack of mortality due to CMV disease. This report confirms that infection is a major complication in adults undergoing UD-CBT.
Saavedra
S
S
Bone Marrow Transplant Unit, Department of Haematology, Hospital Universitario La Fe, Valencia, Spain.
Sanz
G F
GF
Jarque
I
I
Moscardó
F
F
Jiménez
C
C
Lorenzo
I
I
Martín
G
G
Martínez
J
J
De La Rubia
J
J
Andreu
R
R
Mollá
S
S
Llopis
I
I
Fernández
M J
MJ
Salavert
M
M
Acosta
B
B
Gobernado
M
M
Sanz
M A
MA
D000151:Acinetobacter Infections / Q000453:epidemiology / Q000209:etiology; D000293:Adolescent; D000328:Adult; D016470:Bacteremia / Q000453:epidemiology / Q000209:etiology; D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects*; D003586:Cytomegalovirus Infections / Q000453:epidemiology / Q000209:etiology; D004351:Drug Resistance; D005260:Female; D005335:Fever of Unknown Origin / Q000209:etiology; D006086:Graft vs Host Disease / Q000517:prevention & control; D016905:Gram-Negative Bacterial Infections / Q000453:epidemiology / Q000209:etiology; D016908:Gram-Positive Bacterial Infections / Q000453:epidemiology / Q000209:etiology; D019337:Hematologic Neoplasms / Q000150:complications / Q000628:therapy; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D015994:Incidence; D007239:Infections / Q000453:epidemiology / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000453:epidemiology / Q000209:etiology; D013030:Spain / Q000453:epidemiology; D018746:Systemic Inflammatory Response Syndrome / Q000209:etiology / Q000401:mortality; D019172:Transplantation Conditioning / Q000009:adverse effects; D016896:Treatment Outcome; D014766:Viremia / Q000453:epidemiology / Q000209:etiology
D007166:Immunosuppressive Agents